Table V.
Baseline characteristics of patients hospitalized with other SARS-CoV-2 infection (not classified as respiratory or MIS-C)
| Characteristics | Other clinical subgroups, N = 69 |
P value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal | Febrile infant | Neurologic | Diabetes | Hematology or oncology | |||||||
| Total | N = 32 | N = 21 | N = 6 | N = 7 | N = 3 | ||||||
| Age, y | |||||||||||
| Median age (IQR) | 12 | (6-17) | 0 | (0-0) | 3 | (1-11) | 15 | (13-18) | 11 | (1-18) | <.001 |
| Sex | |||||||||||
| Male | 20/32 | (62%) | 11/21 | (52%) | 5/6 | (83%) | 3/7 | (43%) | 2/3 | (67%) | .61 |
| Race/ethnicity | |||||||||||
| Hispanic | 17/30 | (57%) | 7/17 | (41%) | 1/5 | (20%) | 2/6 | (33%) | 1/2 | (50%) | .21 |
| Non-Hispanic black | 7/30 | (23%) | 2/17 | (12%) | 1/5 | (20%) | 3/6 | (50%) | 0/2 | (0%) | |
| Non-Hispanic white | 5/30 | (17%) | 6/17 | (35%) | 3/5 | (60%) | 1/6 | (17%) | 0/2 | (0%) | |
| Non-Hispanic other | 1/30 | (3%) | 2/17 | (12%) | 0/5 | (0%) | 0/6 | (0%) | 1/2 | (50%) | |
| Insurance | |||||||||||
| Private | 8/32 | (25%) | 2/21 | (10%) | 0/6 | (0%) | 2/7 | (29%) | 0/3 | (0%) | .73 |
| Medicaid/Medicare | 22/32 | (69%) | 17/21 | (81%) | 6/6 | (100%) | 5/7 | (71%) | 3/3 | (100%) | |
| Uninsured/self-pay | 1/32 | (3%) | 0/21 | (0%) | 0/6 | (0%) | 0/7 | (0%) | 0/3 | (0%) | |
| Other/unknown | 1/32 | (3%) | 2/21 | (10%) | 0/6 | (0%) | 0/7 | (0%) | 0/3 | (0%) | |
| SES by ZIP code | |||||||||||
| Low SES∗ | 9/32 | (28%) | 4/21 | (19%) | 2/6 | (33%) | 4/7 | (57%) | 0/3 | (0%) | .32 |
| Coexisting conditions | |||||||||||
| Obesity∗ | 3/30 | (10%) | 1/8 | (12%) | 0/4 | (0%) | 0/7 | (0%) | 1/3 | (33%) | .52 |
| Respiratory∗ | 2/32 | (6%) | 0/21 | (0%) | 0/6 | (0%) | 2/7 | (29%) | 0/3 | (0%) | .16 |
| Neurologic∗ | 0/32 | (0%) | 0/21 | (0%) | 1/6 | (17%) | 0/7 | (0%) | 0/3 | (0%) | .13 |
| Immunosuppressed∗ | 1/32 | (3%) | 0/21 | (0%) | 0/6 | (0%) | 0/7 | (0%) | 1/3 | (33%) | .12 |
| Diabetes∗ | 1/32 | (3%) | 0/21 | (0%) | 1/6 | (17%) | 1/7 | (14%) | 0/3 | (0%) | .19 |
| Cardiovascular∗ | 3/32 | (9%) | 1/21 | (5%) | 0/6 | (0%) | 0/7 | (0%) | 0/3 | (0%) | 1.00 |
| History of smoking∗ | 3/27 | (11%) | 0/21 | (0%) | 0/6 | (0%) | 0/4 | (0%) | 0/2 | (0%) | .52 |
| Medical complexity∗ | 5/32 | (16%) | 1/21 | (5%) | 1/6 | (17%) | 1/7 | (14%) | 1/3 | (33%) | .38 |
| COVID-19 testing | |||||||||||
| Only RT-PCR+ | 27/32 | (84%) | 20/21 | (95%) | 5/6 | (83%) | 6/7 | (86%) | 3/3 | (100%) | .65 |
| Only IgG+ | 3/32 | (9%) | 1/21 | (5%) | 0/6 | (0%) | 1/7 | (14%) | 0/3 | (0%) | |
| Both PCR+ and IgG+ | 2/32 | (6%) | 0/21 | (0%) | 1/6 | (17%) | 0/7 | (0%) | 0/3 | (0%) | |
| Admission laboratories, median (IQR) | |||||||||||
| Hemoglobin, g/dL | 13, N = 31 | (12-14) | 13, N = 19 | (11-14) | 12, N = 6 | (12-12) | 14, N = 5 | (14-15) | 11, N = 3 | (6-12) | .017 |
| WBC, × 109/L | 11, N = 32 | (7-16) | 9, N = 19 | (6-13) | 9, N = 6 | (5-10) | 10, N = 5 | (9-14) | 4, N = 3 | (1-12) | .27 |
| Absolute neutrophil count, × 109/L | 7, N = 31 | (4-13) | 3, N = 18 | (2-5) | 4, N = 6 | (2-5) | 7, N = 5 | (6-11) | 3, N = 3 | (1-3) | .004 |
| Absolute lymphocyte count, × 109/L | 2, N = 31 | (1-2) | 3, N = 18 | (2-5) | 3, N = 6 | (3-3) | 2, N = 5 | (2-2) | 1, N = 3 | (0-7) | .010 |
| Platelets, × 109/L | 244, N = 31 | (213-411) | 341, N = 19 | (275-421) | 300, N = 6 | (204-416) | 334, N = 5 | (305-345) | 88, N = 3 | (4-160) | .036 |
| Alanine aminotransferase, U/L | 19, N = 26 | (15-24) | 22, N = 14 | (18-26) | 17, N = 4 | (12-21) | 20, N = 5 | (17-26) | 55, N = 3 | (23-70) | .15 |
| CRP, mg/dL | 7, N = 21 | (2-17) | 0, N = 10 | (0-1) | 10, N = 2 | (5-14) | 2, N = 2 | (0-4) | 1, N = 1 | (1-1) | .073 |
| Coinfections | |||||||||||
| Viral infections | 1/32 | (3%) | 0/21 | (0%) | 1/6 | (17%) | 1/7 | (14%) | 0/3 | (0%) | .19 |
RT-PCR, reverse transcription polymerase chain reaction; WBC, white blood cell.
Data are presented as median (IQR) for continuous measures, and n/total (%) for categorical measures. P values estimated using Fisher exact and Kruskal–Wallis tests for categorical and continuous variables, respectively.
∗
See definitions in Table II.